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Table 1
* Total
N 222
Age 58 (20-72)
HCT-SCI 0-1/2/>3 53/54/90
PS 90-100/70-80/50-60 107/108/7
AML/ALL/MDS/NHL and HD/MM/others 76/10/22/71/35/8
Disease Risk index
Low/Int/High/VHigh
26/132/58/6 12%/59%/26%/3%
MRD/MUD/ MMUD 111/77/34 50%/35%/15%
* HCT-SCI indicates: hematopoietic cell transplantation speciﬁc comor-
bidity index; MRD, Matched related donor; MUD, Matched unrelated donor;
MMUD, Mismatched unrelated donor
Table 2
n 2-y OS 2-y PFS 2-y RR 2-y NRM
All patients 222 64% 54% 28% 20%
Low DRI 26 (12% 92% 69% 8% 13%
Int DRI 132 (59%) 69% 56% 27% 21%
High/VHigh DRI 64 (29%) 43% 40% 38% 31%
> 58 years 120 61% 50% / 27%
< 58 years 102 67% 60% / 16%
MRD 111 67% 53% / 16%
MUD+ MMUD 111 60% 55% / 28%
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Innate and therapy-induced states of immunosuppres-
sion are associated with a variety of potentially infectious
idiopathic clinical syndromes. Using unbiased, next-genera-
tion sequencing, we investigated the metagenome of cord
colitis syndrome (CCS), a recently described transplantation-
associated colitis syndrome, in order to identify a candidate
infectious trigger. Shotgunwhole genome sequencing of DNA
was performed followed by computational classiﬁcation of
reads. A large proportion of reads remained unmapped,
suggesting the presence of a potentially novel organism. In
order to investigate the source of these unmapped reads, de
novo computational assembly of nonhuman reads was per-
formed and yielded 98 contigs of > 2.5kb in length covering
a total of 7.65Mb. Read coverage and GC content was similar
for all of these contigs, suggesting they corresponded to
a common organism. Phylogenetic analysis of this draft
genome revealed that this organism was a novel species,
which we have provisionally named Bradyrhizobium enterica.
PCR conﬁrmed the presence of B. enterica in three additional
CCS patients and demonstrated absence of B. enterica in
normal colon, colon cancer and graft-versus-host disease
controls. In summary, we have demonstrated the assembly of
a novel bacterial draft genome from human tissue specimens
without isolation or culture of the organism. This organism,
provisionally named B. enterica, is associated with CCS sug-
gesting that it may function as an opportunistic human
pathogen.345
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Introduction: We have treated 222 consecutive patients
eligible for allo HSCT with the same RIC from June 2005 up to
March 2012.We particularly studied the impact of age, donor
source and of the recent disease risk index (DRI) published
by Amand et al (Blood 2012).
Patients and methods: All patients were treated for
hematologic malignancies and were prepared with Flu-
darabin (30 mg/m2/D x 5 D, IV Busulfan (3.2 mg/Kg/D x 2
D, and rabbit antithymocyte globulin (rATG) (2.5 mg/Kg/D
x 2 D). All patients received CSA from D-1 with the
addition of MMF in case of MMUD as post graft
immunosuppression.Results: As for August 2012, follow-up is 24 months (4-77).
Patients characteristics are presented in Table 1; median age
was 58 years with 45% and 30% of the patients presenting
with a HCT-SCI > 2 and a high or very high DRI
respectively. 50% of donors were related siblings. Analyses
of outcomes are presented in Table 2. Age only inﬂuenced
NRM (P ¼ .21). Donor origin has no inﬂuence on any
outcome variable. DRI inﬂuenced OS (P ¼ .000017) (Figure
1), PFS (P ¼ .00045) (Figure 2), relapse (P ¼ .0073) and at
a lesser degree NRM (P ¼ .056).
Conclusions: Overall results are promising. They validate the
previously published DRI and indicate populations where
efforts should be focused. Interestingly results are similar
whatever the donor is.346
Post-Transplant Outcome in Patients with Acute Myeloid
Leukemia and Myelodysplasic Syndrome Who Received
Conditioning Regimen Based on Fludarabin, Busulfan and
Anti-Thymoglobulin Prior to Allogeneic Hematopoietic
Stem Cell Transplantation
Didier Blaise 1, Claire Oudin 2, Patrice Chevallier 3, Sabine Furst 4,
Thierry Guillaume 5, Jean EL-Cheikh 2, Roberto Crocchiolo 2,
J. Delaunay 6, Anne Etienne 7, Norbert Vey 7, Mohamad Mohty 8.
1 Bone Marrow Transplant Unit, Institut Paoli Calmettes,
Marseille, Cedex 9, France; 2 Unité de Greffe, Institut
Paoli-Calmettes, Marseille, France; 3 Hematologie, CHU
NANTES, Nantes, France; 4 Institut Paoli Calmettes; 5 University
of Louvain, Brussels, Belgium; 6 Institut Paoli-Calmettes;
7 Hematologie, Institut Paoli-Calmettes, Marseille, France;
8 Hematology Dpt, CHU de Nantes-Hotel-Dieu, Nantes, France
Purpose: Over the years, we have tuned the chemotherapy
dose intensity of a busulfan based RIC regimen with the aim
to better control disease while retaining a low toxicity
proﬁle. Here, we retrospectively analyzed a cohort of patients
with myeloid malignancies treated identically in two French
centers.
Patients and methods: From 2005 to 2010 in Marseille and
Nantes we transplanted 165 patients (median age: 56.8 years
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(N¼124) or MDS (N¼41) following a similar conditioning
regimen but for the dose of busulfan (Bu): 1/Fludarabine (30
mg/m2/day over 5 days) 2/, rabbit ATG (r-ATG) (2.5mg/kg/day
over 2 days) and 3/ i.v. or oral Busulfan (Bu) (130 mg/m2/day
or 3.2 mg/kg respectively over 2 to 4 days) (table 1). Cyclo-
sporin A was given as post graft immunosuppression.
Initially higher Bu doses were proposed to patients under the
age of 55, without comorbidities and with higher risk
diseases.
Results: With a median follow up of 20.7 months, 2 year
overall survival (OS) and PFS were 59.6% (95% CI: 51.8-68.6)
and 54.9% (95% CI: 47-64) respectively. Grade 2-4 and 3-4
acute graft-versus-host diseases (aGvhD) at day 100 was
19.4% and 7.9% respectively. cGvhD (all grades) and extensive
cGvhD were 25% and 14.4% at 1 year post transplantation
respectively. Non relapsemortality (NRM)was 11.7 and 15.4%
at 12 and 24 months. Relapse (CIR) was 24% and 29.7% at 1
and 2 years.
Overall neither the patient age, nor the donor type or the
dose of Busulfan inﬂuenced signiﬁcantly OS, PFS or CIR in the
whole cohort. Surprisingly, NRM was lower after 3 or 4 days
busulfan conditioning regimen (3.6% vs 21.3%,P ¼ .009).
The 93 CR1 AML patients had 2-year OS and PFS of 63.4%
(95% CI: 53.3-75.3) and 60.9% (95%CI: 50.8-72.9) respectively.
Two-year OS reached 66.4% (95%CI: 56.4-81.8) for AML
patients with favorable or intermediate karyotype and 50.5%
(95%CI: 33-77.3) for unfavorable, P ¼ .08. AML patients with
favorable or intermediate karyotype tend to have a better
2-year PFS (63.8%, 95%CI: 52.2-78.1) than unfavorable
karyotype (52%, 95%CI: 34.5-78.3), P ¼ .2.
Patients under the age of 55 (n¼76) present overall
a better outcome than older (OS: 63.9 (CI: 52.7-74.4) vs 56%
(CI: 45.6-68.7), P ¼ .2, PFS: 60.5 (49.7-73.8) vs 50.4% (CI: 40-
63.5),P ¼ .2, NRM: 9.4 vs 20.3%, P ¼ .07). In addition higher
doses of BU improved OS (77.5% vs 47.9%, P ¼ .058), PFS (71.6
vs 46.4%, P ¼ .1), without increase of NRM (2.2% vs 18.7%,
P ¼ .03).
Conclusion: This conditioning regimen using Fludarabin,
Busulfan and r-ATG can result in good OS and PFS probabil-
ities, in myeloid malignancies. Given the patient population
characteristics the NRM can be considered as low. The good
NRM proﬁle of higher doses invite to further developments.347
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Aim: To determine the safety and feasibility of using G-CSF-
mobilized peripheral blood progenitor cells from hap-
loidentical related donors for transplantation in patients
with poor-risk hematological malignancies receiving
reduced intensity conditioning therapy and post-transplant
cyclophosphamide as GVHD prophylaxis.
Methods: Nine patients aged 33 to 65 years (median 48)
with poor prognosis hematological malignancies (4 AML, 1
MDS, 2 Ph+ ALL, 1 DLBCL, 1 ALL) who lacked HLA-matchedrelated or unrelated donors underwent transplantation using
G-CSF-mobilized PBSC from haploidentical relatives, after
receiving reduced intensity conditioning therapy with ﬂu-
darabine, cyclophosphamide, and single fraction TBI 200 cGy.
GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg
IV daily on days +3 and +4, followed by daily oral tacrolimus
and mycophenolate. Median follow-up is 11 months (1-14).
Results were compared with a previous cohort of 12 patients
receiving unmanipulated haploidentical bone marrow.
Results: Neutrophil and platelet recovery (ANC >1.0 median
day 18, range 11-35 ; platelets >20 median day 19, 1-45) was
comparable with 15 and 17 days respectively,for bone
marrow. Six patients had neutropenic fevers, but there was
no mucositis, use of TPN, or early transplant-related death.
Six of 8 assessable patients had complete donor chimerism in
blood T cells and granulocytes at day +28. Two had graft
rejection with only host DNA (one patient with MDS with
high-titre anti-donor HLA antibodies, and one patient with
ALL), as compared with 2 rejections of 12 previous patients
receiving bone marrow grafts. Of the 6 patients with
complete donor chimerism, 1 had stage 3 skin acute GVHD,
but there has been no chronic GVHD or disease relapse. The
MDS patient with graft rejection was re-transplanted after
plasmapheresis and rituximab and IV cyclophosphamide/
busulphan conditioning with PBSC from an alternative hap-
loidentical related donor, and identical GVHD prophylaxis,
and achieved complete donor chimerism.
Conclusion: The use of unmanipulated G-CSF-mobilized
HPC collected from haploidentical relatives appears feasible
for patients receiving reduced intensity conditioning and
high-dose cyclophosphamide as GVHD prophylaxis, with
rates of engraftment, graft rejection and GHVD comparable
to that seen with haploidentical bone marrow. This protocol
offers an allogeneic transplant option with low cost and
toxicity for patients without a HLA-identical donor.348
Evaluation of Transjugular Liver Biopsy in the Diagnosis
of Early Hepatic Dysfunction After Allogeneic
Hematopoietic Cell Transplantation
Nerea Castillo 1,2, Pere Barba 3, Mercedes Perez 4,
Helena Allende 5, M Aranzazu Gelabert 5, Francesc Bosch 5,
David Valcarcel 2,3. 1 Hematology, Hospital Vall d'Hebron,
Universitat Autònoma de Barcelona, Barcelona; 2Hospital Vall
d'Hebron. Universitat Autònoma de Barcelona, Spain;
3Hematology, Hospital Vall d'Hebron. Universitat Autònoma de
Barcelona; 4 Interventional radiology, Hospital Vall d'Hebron.
Universitat Autònoma de Barcelona; 5Hospital Vall d'Hebron.
Universitat Autònoma de Barcelona
Introduction: Liver biopsy might be necessary in the diag-
nosis of liver dysfunction after allogeneic stem cell trans-
plantation (allo-SCT) but transparietal (TP) access is usually
not possible. Transjugular liver biopsies (TJLB) may offer
a good alternative. We retrospectively analyzed the role of
TJLB in the diagnosis of early hepatic dysfunction after allo-
SCT.
Methods: We included all consecutive allo-SCT recipients
undergoing TJLB in our centre from May 1997 to September
2011. Median follow-up for survivors was 28 months (1-57).
According to our protocol, TJLB instead of TP access was
preferred in patients with platelet count <50x10e9/L, coag-
ulation abnormalities or unstable medical condition. TJLB
were performed using a needle coated with a ﬂexible cath-
eter through jugular access. Pathological samples were
analyzed by an experienced pathologist in the centre and
retrospectively revised.
